{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:20:36Z","timestamp":1788733236332,"version":"build-2803163510"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-026-04631-6","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:25:06Z","timestamp":1777692306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Continuous administration of lenvatinib after first documented disease progression in patients with radioiodine-refractory thyroid cancer"],"prefix":"10.1007","volume":"91","author":[{"given":"Naoki","family":"Fukuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumpei","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Urasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Tomomatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Mitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"issue":"9940","key":"4631_CR1","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/s0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"M.S. Brose, C.M. Nutting, B. Jarzab et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384(9940), 319\u2013328 (2014). https:\/\/doi.org\/10.1016\/s0140-6736(14)60421-9","journal-title":"Lancet"},{"issue":"7","key":"4631_CR2","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/nejmoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"M. Schlumberger, M. Tahara, L.J. Wirth et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372(7), 621\u2013630 (2015). https:\/\/doi.org\/10.1056\/nejmoa1406470","journal-title":"N. Engl. J. Med."},{"key":"4631_CR3","unstructured":"National Comprehensive Cancer Network. NCCN guidelines. Thyroid carcinoma. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/thyroid.pdf. Accessed Oct 24, 2025."},{"issue":"3","key":"4631_CR4","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network, Integrated genomic characterization of papillary thyroid carcinoma. Cell 159(3), 676\u2013690 (2014). https:\/\/doi.org\/10.1016\/j.cell.2014.09.050","journal-title":"Cell"},{"issue":"11","key":"4631_CR5","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1210\/clinem\/dgae271","volume":"109","author":"S Toda","year":"2024","unstructured":"S. Toda, Y. Hiroshima, H. Iwasaki, K. Masudo, Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan. J. Clin. Endocrinol. Metab. 109(11), 2784\u20132792 (2024). https:\/\/doi.org\/10.1210\/clinem\/dgae271","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"10","key":"4631_CR6","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1089\/thy.2022.0115","volume":"32","author":"NL Busaidy","year":"2022","unstructured":"N.L. Busaidy, B. Konda, L. Wei et al. Dabrafenib Versus Dabrafenib + Trametinib in BRAF-Mutated radioactive iodine refractory differentiated thyroid cancer: Results of a Randomized, Phase 2, Open-Label Multicenter Trial. Thyroid 32(10), 1184\u20131192 (2022). https:\/\/doi.org\/10.1089\/thy.2022.0115","journal-title":"Thyroid"},{"issue":"4","key":"4631_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1089\/thy.2023.0547","volume":"34","author":"M Tahara","year":"2024","unstructured":"M. Tahara, N. Kiyota, H. Imai et al. A Phase 2 study of encorafenib in combination with binimetinib in patients with metastatic BRAF-Mutated thyroid cancer in Japan. Thyroid 34(4), 467\u2013476 (2024). https:\/\/doi.org\/10.1089\/thy.2023.0547","journal-title":"Thyroid"},{"issue":"8","key":"4631_CR8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","volume":"35","author":"MD Ringel","year":"2025","unstructured":"M.D. Ringel, J.A. Sosa, Z. Baloch et al. 2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer. Thyroid 35(8), 841\u2013985 (2025). https:\/\/doi.org\/10.1177\/10507256251363120","journal-title":"Thyroid"},{"key":"4631_CR9","unstructured":"FDA grants accelerated approval to dabrafenib in combination with trametinib for unresectable or metastatic solid tumors with BRAF V600E mutation. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-dabrafenib-combination-trametinib-unresectable-or-metastatic-solid. Accessed Feb 2, 2026"},{"key":"4631_CR10","unstructured":"Summary of Investigation Results Dabrafenib mesilate Trametinib dimethyl sulfoxide https:\/\/www.pmda.go.jp\/files\/000274284.pdf. Accessed Feb 2, 2026"},{"issue":"2","key":"4631_CR11","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1210\/clinem\/dgaf366","volume":"111","author":"S Hamidi","year":"2026","unstructured":"S. Hamidi, A. Maniakas, N.S. Akhave et al. Characterization of advanced RAS-driven follicular-derived thyroid cancers and review of future therapeutic avenues. J. Clin. Endocrinol. Metab. 111(2), 471\u2013483 (2026). https:\/\/doi.org\/10.1210\/clinem\/dgaf366","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"7","key":"4631_CR12","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1210\/jc.2018-00277","volume":"103","author":"NG Nicolson","year":"2018","unstructured":"N.G. Nicolson, T.D. Murtha, W. Dong et al. Comprehensive genetic analysis of follicular thyroid carcinoma predicts prognosis independent of histology. J. Clin. Endocrinol. Metab. 103(7), 2640\u20132650 (2018). https:\/\/doi.org\/10.1210\/jc.2018-00277","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"13","key":"4631_CR13","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","volume":"24","author":"N Pozdeyev","year":"2018","unstructured":"N. Pozdeyev, L.M. Gay, E.S. Sokol et al. Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin. Cancer Res. 24(13), 3059\u20133068 (2018). https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0373","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"4631_CR14","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","volume":"22","author":"MS Brose","year":"2021","unstructured":"M.S. Brose, B. Robinson, S.I. Sherman et al. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 22(8), 1126\u20131138 (2021). https:\/\/doi.org\/10.1016\/S1470-2045(21)00332-6","journal-title":"Lancet Oncol."},{"issue":"9","key":"4631_CR15","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.3390\/cancers13092279","volume":"13","author":"N Fukuda","year":"2021","unstructured":"N. Fukuda, S. Takahashi, Clinical indications for treatment with multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer. Cancers 13(9), 2279 (2021). https:\/\/doi.org\/10.3390\/cancers13092279","journal-title":"Cancers"},{"issue":"2","key":"4631_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"E.A. Eisenhauer, P. Therasse, J. Bogaerts et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 45(2), 228\u2013247 (2009). https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur. J. Cancer."},{"key":"4631_CR17","unstructured":"WHO Classification of Tumours of Endocrine Organs. Vol 10. 5th ed. Lyon, France: WHO\/IARC Press"},{"issue":"7","key":"4631_CR18","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s10147-020-01684-z","volume":"25","author":"S Iwasa","year":"2020","unstructured":"S. Iwasa, T. Kudo, D. Takahari et al. Practical guidance for the evaluation of disease progression and the decision to change treatment in patients with advanced gastric cancer receiving chemotherapy. Int. J. Clin. Oncol. 25(7), 1223\u20131232 (2020). https:\/\/doi.org\/10.1007\/s10147-020-01684-z","journal-title":"Int. J. Clin. Oncol."},{"issue":"3","key":"4631_CR19","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Y. Kanda, Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 48(3), 452\u2013458 (2013). https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transpl."},{"issue":"suppl_2","key":"4631_CR20","doi-asserted-by":"publisher","first-page":"S1559","DOI":"10.1016\/j.annonc.2025.08.3601","volume":"36","author":"LJ Wirth","year":"2025","unstructured":"L.J. Wirth, Efficacy and safety of dabrafenib plus trametinib (D+T) in patients with radioactive iodine (RAI)-refractory BRAF V600-mutant differentiated thyroid cancer (DTC). Ann. Oncol. 36(suppl_2), S1559 (2025). https:\/\/doi.org\/10.1016\/j.annonc.2025.08.3601","journal-title":"Ann. Oncol."},{"key":"4631_CR21","unstructured":"Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer. https:\/\/clinicaltrials.gov\/study\/NCT06475989. Accessed Feb 2, 2026"},{"issue":"10","key":"4631_CR22","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s10147-024-02581-5","volume":"29","author":"R Onaga","year":"2024","unstructured":"R. Onaga, T. Enokida, S. Okano et al. Clinical impact of a dose-escalation strategy for lenvatinib in differentiated thyroid cancer. Int. J. Clin. Oncol. 29(10), 1435\u20131443 (2024). https:\/\/doi.org\/10.1007\/s10147-024-02581-5","journal-title":"Int. J. Clin. Oncol."},{"key":"4631_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1154771","volume":"13","author":"Y Shibutani","year":"2023","unstructured":"Y. Shibutani, S. Suzuki, A. Sagara et al. Impact of lenvatinib-induced proteinuria and renal dysfunction in patients with thyroid cancer. Front. Oncol. 13, 1154771 (2023). https:\/\/doi.org\/10.3389\/fonc.2023.1154771","journal-title":"Front. Oncol."},{"issue":"4","key":"4631_CR24","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1507\/endocrj.ej23-0378","volume":"71","author":"N Fukuda","year":"2024","unstructured":"N. Fukuda, K. Toda, H. Suto et al. Clinical impact of proteinuria on renal function and treatment outcomes in patients with radioiodine-refractory thyroid cancer treated with lenvatinib. Endocr. J. 71(4), 363\u2013371 (2024). https:\/\/doi.org\/10.1507\/endocrj.ej23-0378","journal-title":"Endocr. J."},{"issue":"1","key":"4631_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s1470-2045(12)70477-1","volume":"14","author":"J Bennouna","year":"2013","unstructured":"J. Bennouna, J. Sastre, D. Arnold et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 14(1), 29\u201337 (2013). https:\/\/doi.org\/10.1016\/s1470-2045(12)70477-1","journal-title":"Lancet Oncol."},{"issue":"5","key":"4631_CR26","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/s1470-2045(15)70127-0","volume":"16","author":"J Tabernero","year":"2015","unstructured":"J. Tabernero, T. Yoshino, A.L. Cohn et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol. 16(5), 499\u2013508 (2015). https:\/\/doi.org\/10.1016\/s1470-2045(15)70127-0","journal-title":"Lancet Oncol."},{"issue":"28","key":"4631_CR27","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/jco.2012.42.8201","volume":"30","author":"Van","year":"2012","unstructured":"Van, E. Cutsem, J. Tabernero, R. Lakomy et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J. Clin. Oncol. 30(28), 3499\u20133506 (2012). https:\/\/doi.org\/10.1200\/jco.2012.42.8201","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"4631_CR28","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/nejmoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"G.W. Prager, J. Taieb, M. Fakih et al. Trifluridine-Tipiracil and bevacizumab in refractory metastatic colorectal cancer. N. Engl. J. Med. 388(18), 1657\u20131667 (2023). https:\/\/doi.org\/10.1056\/nejmoa2214963","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"4631_CR29","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1158\/1078-0432.ccr-09-3100","volume":"16","author":"A Bagri","year":"2010","unstructured":"A. Bagri, L. Berry, B. Gunter et al. Effects of anti-VEGF treatment duration on tumor growth, tumor regrowth, and treatment efficacy. Clin. Cancer Res. 16(15), 3887\u20133900 (2010). https:\/\/doi.org\/10.1158\/1078-0432.ccr-09-3100","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"4631_CR30","doi-asserted-by":"publisher","first-page":"H560","DOI":"10.1152\/ajpheart.00133.2005","volume":"290","author":"T Kamba","year":"2006","unstructured":"T. Kamba, B.Y. Tam, H. Hashizume et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am. J. Physiol. Heart Circ. Physiol 290(2), H560\u2013H576 (2006). https:\/\/doi.org\/10.1152\/ajpheart.00133.2005","journal-title":"Am. J. Physiol. Heart Circ. Physiol"},{"issue":"11","key":"4631_CR31","doi-asserted-by":"publisher","first-page":"e19408","DOI":"10.1097\/md.0000000000019408","volume":"99","author":"H Yamazaki","year":"2020","unstructured":"H. Yamazaki, K. Sugino, K. Matsuzu et al. Rapid disease progression after discontinuation of lenvatinib in thyroid cancer. Medicine 99(11), e19408 (2020). https:\/\/doi.org\/10.1097\/md.0000000000019408","journal-title":"Medicine"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04631-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-026-04631-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-026-04631-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:25:11Z","timestamp":1777692311000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-026-04631-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4631"],"URL":"https:\/\/doi.org\/10.1007\/s12020-026-04631-6","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"25 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review board of the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (2024-GB-082) and adhered to the guidelines outlined in the Helsinki Declaration of 1964 and its subsequent revisions. The need for informed consent was waived in view of the retrospective observational nature of the research. However, in accordance with government policy in Japan, patients had the opportunity to decline participation via an opt-out route.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"N.F. has received personal fees from Eisai that are not relevant to the submitted work. The other authors report no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"166"}}